Advertisement Respiratory Virus Drug Development Services - Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about InPheno

Respiratory Virus Drug Development Services

InPheno

InPheno is dedicated to advancing the discovery and development of new antivirals to fight off major causes of respiratory tract infections. InPheno is offering services in influenza, respiratory syncytial virus (RSV) and parainfluenza viruses (PIV).

Our assays are monitoring the inhibition of plaque formation or of virus-induced cytopathic effects (CPE) by the compounds under study. These assays can also be used to survey the antibody response in vaccinees or to select neutralizing monoclonal antibodies.

Influenza

InPheno’s assays run with either type A or B influenza reference viruses. A library of ca. 10’000 recent clinical isolates is available for your compound profiling needs.

Respiratory Syncytial Virus and Parainfluenza Virus

In addition to assays using live viruses, InPheno is currently developing entry and replicon-based assays for RSV and PIV.

Quick Contact Respiratory Virus Drug Development Services